#United States #Fremont #Q'Apel Medical #SelectFlex™ #Neurovascular Access

Q'Apel Medical Secures CE Mark for Armadillo SelectFlex™ System

Q'Apel Medical, a medical device company specializing in neurovascular interventions, has made significant strides in the field with the recent CE mark certification of its revolutionary Armadillo SelectFlex™ Neurovascular Access System. This achievement marks a notable milestone for the company, affirming its commitment to innovation and advancing patient care.

The Armadillo SelectFlex™ System is a state-of-the-art 7F device that integrates Q'Apel's patented SelectFlex™ Technology. Designed specifically for navigating the complexities of neurovascular anatomy, this system enhances an operator's ability to perform delicate procedures without the complications commonly associated with traditional access systems.

The Challenge of Neurovascular Access

Neurovascular access poses a range of challenges due to the intricate and often tortuous architecture of the brain's blood vessels. Conventional approaches relying on rigid catheters often lack the necessary flexibility and support essential for successful device placement. As Dr. Pascal Jabbour, a leading expert in neurosurgery from Thomas Jefferson University Hospital, points out, achieving the ideal balance of trackability and support during interventions is crucial.

The Armadillo SelectFlex™ provides a versatile solution, allowing users to seamlessly transition between high trackability and robust support using just a small injection of saline. This transformative technology enables healthcare providers to perform interventions more effectively, leading to potentially better outcomes for patients.

Simplifying Procedures with Innovative Design

One of the standout features of the Armadillo SelectFlex™ System is its ability to simplify access procedures that are traditionally complex and cumbersome. The system's low-profile 7F catheter facilitates a biaxial approach, which not only expedites delicate procedures but also reduces the overall complexity and costs often associated with standard tri-axial configurations. As stated by Jodie Fam, CEO of Q'Apel Medical, the technology addresses the shortcomings of existing neurovascular access devices, allowing hospitals to standardize usage, minimize inventory needs, and lower the cost of each procedure.

With the CE mark approval now in hand, Q'Apel Medical is poised to expand its presence in the international market. The company aims to leverage its success in the U.S. to introduce the Armadillo SelectFlex™ System across Europe and beyond, ensuring that healthcare providers have access to this cutting-edge technology.

Looking Ahead: The Future of Neurovascular Interventions

As Q'Apel Medical continues to innovate, the focus remains on addressing clinical challenges that patients and healthcare providers face in neurovascular interventions. Their commitment to developing high-quality, uniquely engineered products, in collaboration with neurovascular specialists, positions the company as a leader in the field.

In conclusion, the CE mark certification for the Armadillo SelectFlex™ Neurovascular Access System not only highlights Q'Apel Medical's dedication to enhancing patient outcomes but also signifies a crucial step forward in the evolution of medical technology aimed at revolutionizing neurovascular care. This advancement promises to benefit both medical professionals and patients alike by streamlining procedures while ensuring safety and effectiveness.

For more details on the Armadillo SelectFlex™ System and its capabilities, visit Q'Apel Medical's official website.